{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:22:59Z","timestamp":1778595779364,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ym0126095h0001"],"award-info":[{"award-number":["22ym0126095h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dm0107071"],"award-info":[{"award-number":["JP20dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19dm0107071"],"award-info":[{"award-number":["JP19dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJCR21P1"],"award-info":[{"award-number":["JPMJCR21P1"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06644"],"award-info":[{"award-number":["22K06644"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jphs.2023.02.008","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T02:02:56Z","timestamp":1678500176000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice"],"prefix":"10.1016","volume":"152","author":[{"given":"Haoyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariko","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-7847","authenticated-orcid":false,"given":"Ichiro","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jphs.2023.02.008_bib1","doi-asserted-by":"crossref","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"11","key":"10.1016\/j.jphs.2023.02.008_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jphs.2023.02.008_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jphs.2023.02.008_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fncel.2016.00293","article-title":"Early degeneration of both dopaminergic and serotonergic axons - a common mechanism in Parkinson's disease","volume":"10","author":"Grosch","year":"2016","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1016\/j.jphs.2023.02.008_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1471-4914(03)00020-0","article-title":"Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease","volume":"9","author":"Barzilai","year":"2003","journal-title":"Trends Mol Med"},{"issue":"10","key":"10.1016\/j.jphs.2023.02.008_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","article-title":"alpha-Synuclein misfolding and aggregation: implications in Parkinson's disease pathogenesis","volume":"1867","author":"Mehra","year":"2019","journal-title":"Biochim Biophys Acta, Proteins Proteomics"},{"key":"10.1016\/j.jphs.2023.02.008_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnana.2014.00159","article-title":"Alpha-synuclein spreading in Parkinson's disease","volume":"8","author":"Recasens","year":"2014","journal-title":"Front Neuroanat"},{"key":"10.1016\/j.jphs.2023.02.008_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-014-0073-2","article-title":"Alpha-synuclein biology in Lewy body diseases","volume":"6","author":"Kim","year":"2014","journal-title":"Alzheimer's Res Ther"},{"issue":"5","key":"10.1016\/j.jphs.2023.02.008_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050560","article-title":"Impact of fatty acid-binding proteins in alpha-synuclein-induced mitochondrial injury in synucleinopathy","volume":"9","author":"Cheng","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jphs.2023.02.008_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fnins.2016.00408","article-title":"Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other Lewy body disorders","volume":"10","author":"Ingelsson","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jphs.2023.02.008_bib11","article-title":"Models of \u03b1-synuclein aggregation in Parkinson's disease","volume":"2","author":"Rosa Mar\u00eda Gir\u00e1ldez-P\u00e9rez","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"10.1016\/j.jphs.2023.02.008_bib12","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1074\/jbc.M115.705095","article-title":"Effects of serine 129 phosphorylation on alpha-synuclein aggregation, membrane association, and internalization","volume":"291","author":"Samuel","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2023.02.008_bib13","article-title":"Phosphorylation induces distinct alpha-synuclein strain formation","volume":"6","author":"Ma","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jphs.2023.02.008_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1529\/biophysj.105.071571","article-title":"Fatty acid binding proteins: same structure but different binding mechanisms? Molecular dynamics simulations of intestinal fatty acid binding protein","volume":"90","author":"Friedman","year":"2006","journal-title":"Biophys J"},{"issue":"27","key":"10.1016\/j.jphs.2023.02.008_bib15","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","article-title":"FABP3 protein promotes alpha-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity","volume":"289","author":"Shioda","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.jphs.2023.02.008_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062230","article-title":"Fatty acid binding protein 3 enhances the spreading and toxicity of alpha-synuclein in mouse brain","volume":"21","author":"Yabuki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.02.008_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1020502624234","article-title":"Insights into binding of fatty acids by fatty acid binding proteins","volume":"239","author":"Hanhoff CLaFS","year":"2002","journal-title":"Mol Cell Biochem"},{"issue":"21","key":"10.1016\/j.jphs.2023.02.008_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215358","article-title":"Fatty acid-binding protein 3 is critical for alpha-synuclein uptake and MPP(+)-Induced mitochondrial dysfunction in cultured dopaminergic neurons","volume":"20","author":"Kawahata","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.02.008_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103582","article-title":"A\u00a0novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models","volume":"72","author":"Cheng","year":"2021","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.jphs.2023.02.008_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120635","article-title":"Fatty acid binding protein 5 mediates cell death by psychosine exposure through mitochondrial macropores formation in oligodendrocytes","volume":"8","author":"Cheng","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jphs.2023.02.008_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010049","article-title":"Dopamine D2 long receptors are critical for caveolae-mediated alpha-synuclein uptake in cultured dopaminergic neurons","volume":"9","author":"Kawahata","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.jphs.2023.02.008_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41401-021-00675-8","article-title":"Fatty acid-binding protein 7 triggers \u03b1-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress","volume":"43","author":"Cheng","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jphs.2023.02.008_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.brainres.2018.11.036","article-title":"Development of FABP3 ligands that inhibit arachidonic acid-induced alpha-synuclein oligomerization","volume":"1707","author":"Cheng","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2023.02.008_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neuropharm.2019.03.029","article-title":"Inhibition of MPTP-induced alpha-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice","volume":"150","author":"Matsuo","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jphs.2023.02.008_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172891","article-title":"Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice","volume":"191","author":"Haga","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jphs.2023.02.008_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroscience.2013.11.051","article-title":"Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice","volume":"259","author":"Yabuki","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.jphs.2023.02.008_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1471-4159.2011.07608.x","article-title":"Reduced calcium\/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired\u00a0cognitive function in MPTP-treated mice","volume":"120","author":"Moriguchi","year":"2012","journal-title":"J\u00a0Neurochem"},{"issue":"1","key":"10.1016\/j.jphs.2023.02.008_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yexmp.2008.10.004","article-title":"Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice","volume":"86","author":"Aoki","year":"2009","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"10.1016\/j.jphs.2023.02.008_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1471-4159.2009.06072.x","article-title":"Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions","volume":"109","author":"Gibrat","year":"2009","journal-title":"J\u00a0Neurochem"},{"issue":"5","key":"10.1016\/j.jphs.2023.02.008_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00401-022-02491-8","article-title":"Stress-inducible phosphoprotein 1 (HOP\/STI1\/STIP1) regulates the accumulation and toxicity of alpha-synuclein in\u00a0vivo","volume":"144","author":"Lackie","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.jphs.2023.02.008_bib31","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","article-title":"Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain","volume":"30","author":"Shioda","year":"2010","journal-title":"J\u00a0Neurosci"},{"issue":"2","key":"10.1016\/j.jphs.2023.02.008_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0014-4886(03)00342-X","article-title":"Enhanced substantia nigra mitochondrial pathology in human \u03b1-synuclein transgenic mice after treatment with MPTP111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"186","author":"Song","year":"2004","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.jphs.2023.02.008_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","article-title":"\u03b1-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP","volume":"74","author":"Miquel Vila","year":"2000","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jphs.2023.02.008_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/NDT.S235562","article-title":"Phosphorylation of tau and alpha-synuclein induced neurodegeneration in MPTP mouse model of Parkinson's disease","volume":"16","author":"Hu","year":"2020","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"1","key":"10.1016\/j.jphs.2023.02.008_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12264-012-1050-z","article-title":"Progression of motor symptoms in Parkinson's disease","volume":"28","author":"Xia","year":"2012","journal-title":"Neurosci Bull"},{"issue":"4","key":"10.1016\/j.jphs.2023.02.008_bib36","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson's disease: a promising direction of therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.jphs.2023.02.008_bib37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.neuroimage.2019.01.062","article-title":"Functional neuroanatomical review of the ventral tegmental area","volume":"191","author":"Trutti","year":"2019","journal-title":"Neuroimage"},{"issue":"Suppl 1","key":"10.1016\/j.jphs.2023.02.008_bib38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson's disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J\u00a0Neurochem"},{"issue":"2-3","key":"10.1016\/j.jphs.2023.02.008_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.baga.2015.06.001","article-title":"The vulnerable ventral tegmental area in Parkinson's disease","volume":"5","author":"Alberico","year":"2015","journal-title":"Basal Ganglia"},{"issue":"1","key":"10.1016\/j.jphs.2023.02.008_bib40","first-page":"19","article-title":"MPTP mouse models of Parkinson's disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.jphs.2023.02.008_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","article-title":"The role of Ser129 phosphorylation of \u03b1-synuclein in neurodegeneration of Parkinson's disease: a review of in\u00a0vivo models","volume":"24","author":"Sato","year":"2013","journal-title":"Rev Neurosci"},{"issue":"11","key":"10.1016\/j.jphs.2023.02.008_bib43","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/ijms23116216","article-title":"Pathogenic impact of alpha-synuclein phosphorylation and its kinases in alpha-synucleinopathies","volume":"23","author":"Kawahata","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:02:20Z","timestamp":1778594540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861323000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1347861323000051"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2023.02.008","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2023.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}